CEO received an award of 45K KRYS derivative securities | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Feb 27, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Mar 3, 2026
CEOGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001298709-26-000002
- Filed / recorded
Added to OQROOct 6, 2026, 7:59 PM UTC Data qualityVerified: identifiers matched exactly IssuerKrystal Biotech, Inc. Reporting personKrish S Krishnan RelationshipDirector, Officer, 10% owner Officer titlePresident and CEO SecurityStock Option (Right to Buy) TableDerivative (Table II) Transaction dateFeb 27, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- The stock options vests in four equal annual installments beginning on February 27, 2027.